['obesity']
['lik066', 'placebo']

        Inclusion Criteria:

          -  Patients with obesity disease and inadequately controlled body weight with diet and/or
             exercise

          -  BMI ≥ 25 kg/m^2 combined with at least two obesity-related comorbidities, or BMI ≥ 35
             kg/m^2 at least one obesity-related comorbidity

          -  Patients with FPG ≥ 110 mg/dL and/or 5.6% ≤ HbA1c ≤ 10.0%, or T2DM with HbA1c ≤ 10.0%

          -  Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female

          -  Visceral fat area ≥ 100 cm^2

          -  Agreement to comply with the study-required life-style intervention and treatment
             during the full duration of the study

        Exclusion Criteria:

          -  Pregnancy or lactating women

          -  Use of pharmacologically active weight-loss medications

          -  Bariatric surgery

          -  Ketoacidosis, lactic acidosis, hyperosmolar coma

          -  Symptomatic genital ingection or urinary tract infection in the 4 weeks prior to
             screening

          -  Gastro-intestinal (GI) disorders associated with chronic diarrhea

          -  Congestive heart failure, New York Heart Association (NYHA) class III or IV
      